Management of advanced breast cancer with the epothilone B analog, ixabepilone
William GradisharRobert H Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, IL, USAAbstract: Despite the activity of standard chemotherapies in advanced breast cancer, disease progression remains inevitable. Most patients exposed to anthracyclines and t...
Saved in:
Main Author: | William Gradishar (Author) |
---|---|
Format: | Book |
Published: |
Dove Medical Press,
2009-06-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Profile and potential of ixabepilone in the treatment of pancreatic cancer
by: Smaglo BG, et al.
Published: (2014) -
Systematic review on the efficacy and safety of ixabepilone-based chemotherapy regimen in triple-negative breast cancer
by: Maghfira Rahma Azizah, et al.
Published: (2024) -
Comparison of PLA-Based Micelles and Microspheres as Carriers of Epothilone B and Rapamycin. The Effect of Delivery System and Polymer Composition on Drug Release and Cytotoxicity against MDA-MB-231 Breast Cancer Cells
by: Katarzyna Jelonek, et al.
Published: (2021) -
Advances in Analog Circuits
Published: (2011) -
Tissue distribution and tumor uptake of folate receptor-targeted epothilone folate conjugate, BMS-753493, in CD2F1 mice after systemic administration
by: Hong Shen, et al.
Published: (2016)